Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms
| Status: | Completed |
|---|---|
| Conditions: | Smoking Cessation, Tobacco Consumers |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 64 |
| Updated: | 4/17/2018 |
| Start Date: | March 16, 2010 |
| End Date: | November 29, 2013 |
Background:
- Researchers have been studying behavioral components of nicotine addiction by looking at
how drugs have a reinforcing effect, connecting the stimulation provided by the drug
(nicotine) to the behavior that produces it (smoking). Based on previous studies, researchers
are interested in learning more about how nicotine affects current smokers' responses to
psychological tests and smoking-related cues, and in studying whether certain kinds of
genetic background may affect smokers' responses to these kinds of studies.
Objectives:
- To compare the effect of nicotine versus denicotinized cigarettes during specific
psychological tests.
- To compare the effects of smoking cues versus neutral cues on craving, mood, and
autonomic response.
- To study the effect of genes on nicotine reinforcement and smoking-cue reactivity.
Eligibility:
- Individuals between 18 and 64 years of age who are current smokers (at least 10 cigarettes
per day for at least 1 year) and are not currently interested in reducing their smoking or
seeking treatment for tobacco dependence.
Design:
- Pilot session:
- Participants will practice smoking using the measuring equipment that will be used in
the study.
- After successful practice, participants will read or listen to music for 1 hour, during
which they are not allowed to smoke.
- After the 1-hour period, participants will sample study cigarettes that have different
levels of nicotine, and will be asked to guess whether the cigarettes are normal study
cigarettes or denicotinized cigarettes.
- Baseline session:
- Blood, urine, and breath samples will be taken at the start of the session.
- Participants will smoke part of an initial cigarette, and then will read or listen to
music for 1 hour, during which they are not allowed to smoke.
- After the 1-hour period, participants will give another breath sample and will complete
questionnaires about mood and concentration levels.
- Trial sessions:
- Participants will smoke study cigarettes, and will be asked to either respond to
questions about perceived nicotine levels in the cigarettes or press a lever for the
chance to be rewarded with additional puffs of the cigarette. After the session,
participants will give another breath sample and will complete questionnaires about mood
and concentration levels.
- Participants will also participate in cue-reactivity sessions to test the body's
physiological response to smoking cues (a pack of cigarettes) and neutral cues (a pack
of unsharpened pencils). After the session, participants will complete questionnaires on
mood and concentration 15, 30, 45, and 60 minutes after the session.
- At the conclusion of the last experimental session, participants will discuss the study
with researchers, and may receive a referral list of smoking treatment programs.
- Researchers have been studying behavioral components of nicotine addiction by looking at
how drugs have a reinforcing effect, connecting the stimulation provided by the drug
(nicotine) to the behavior that produces it (smoking). Based on previous studies, researchers
are interested in learning more about how nicotine affects current smokers' responses to
psychological tests and smoking-related cues, and in studying whether certain kinds of
genetic background may affect smokers' responses to these kinds of studies.
Objectives:
- To compare the effect of nicotine versus denicotinized cigarettes during specific
psychological tests.
- To compare the effects of smoking cues versus neutral cues on craving, mood, and
autonomic response.
- To study the effect of genes on nicotine reinforcement and smoking-cue reactivity.
Eligibility:
- Individuals between 18 and 64 years of age who are current smokers (at least 10 cigarettes
per day for at least 1 year) and are not currently interested in reducing their smoking or
seeking treatment for tobacco dependence.
Design:
- Pilot session:
- Participants will practice smoking using the measuring equipment that will be used in
the study.
- After successful practice, participants will read or listen to music for 1 hour, during
which they are not allowed to smoke.
- After the 1-hour period, participants will sample study cigarettes that have different
levels of nicotine, and will be asked to guess whether the cigarettes are normal study
cigarettes or denicotinized cigarettes.
- Baseline session:
- Blood, urine, and breath samples will be taken at the start of the session.
- Participants will smoke part of an initial cigarette, and then will read or listen to
music for 1 hour, during which they are not allowed to smoke.
- After the 1-hour period, participants will give another breath sample and will complete
questionnaires about mood and concentration levels.
- Trial sessions:
- Participants will smoke study cigarettes, and will be asked to either respond to
questions about perceived nicotine levels in the cigarettes or press a lever for the
chance to be rewarded with additional puffs of the cigarette. After the session,
participants will give another breath sample and will complete questionnaires about mood
and concentration levels.
- Participants will also participate in cue-reactivity sessions to test the body's
physiological response to smoking cues (a pack of cigarettes) and neutral cues (a pack
of unsharpened pencils). After the session, participants will complete questionnaires on
mood and concentration 15, 30, 45, and 60 minutes after the session.
- At the conclusion of the last experimental session, participants will discuss the study
with researchers, and may receive a referral list of smoking treatment programs.
Objectives: 1) to compare the reinforcing efficacy of nicotine versus denicotinized
cigarettes using a forced choice and an operant response procedure, 2) to compare the effects
of smoking cues versus neutral cues on craving, mood, and autonomic responsivity, and 3) to
explore potential associations between several genetic polymorphisms and the phenotypic
measures of nicotine reinforcement and smoking-cue reactivity.
Study population: 175 adult smokers (35 for pilot study I, 60 for pilot stufy II and 80 for
main study).
Design: Placebo-controlled, within-subjects design. Pilot studies will entail 1-2 sessions.
Main study will entail one baseline/adaptation session and 5-10 experimental sessions.
Outcome Measures:
Behavioral Measures
During forced-choice sessions, primary measure is the percentage of nicotine cigarette puffs
chosen and taken during choice trials. During operant response sessions, primary measures
include breakpoint (final ratio completed), total number of responses, and number of
cigarette puffs earned and taken. During cue-reactivity sessions, primary measures include
craving, mood, and autonomic responsivity (heart rate, blood pressure, skin conductance, and
skin temperature).
Genetic Measures
The following genetic polymorphisms will be assayed: 1) C/T rs2023239 variant of the CB1R
gene, 2) the Ser/Gly rs6280 variant of DRD3 gene, and 3) variants of the CYP2A6 gene.
Secondary Measures
Secondary study measures include baseline smoking history, FTND, TCQ-SF, mood form, CO, and
urinary cotinine and 3-hydroxycotinine. The ratio of 3-hydroxycotinine/cotinine is a
phenotypic biomarker of the rate of nicotine metabolism, which has been shown to be
associated with CYP2A6 genotype, level of nicotine dependence, various smoking behaviors, and
treatment outcome.
cigarettes using a forced choice and an operant response procedure, 2) to compare the effects
of smoking cues versus neutral cues on craving, mood, and autonomic responsivity, and 3) to
explore potential associations between several genetic polymorphisms and the phenotypic
measures of nicotine reinforcement and smoking-cue reactivity.
Study population: 175 adult smokers (35 for pilot study I, 60 for pilot stufy II and 80 for
main study).
Design: Placebo-controlled, within-subjects design. Pilot studies will entail 1-2 sessions.
Main study will entail one baseline/adaptation session and 5-10 experimental sessions.
Outcome Measures:
Behavioral Measures
During forced-choice sessions, primary measure is the percentage of nicotine cigarette puffs
chosen and taken during choice trials. During operant response sessions, primary measures
include breakpoint (final ratio completed), total number of responses, and number of
cigarette puffs earned and taken. During cue-reactivity sessions, primary measures include
craving, mood, and autonomic responsivity (heart rate, blood pressure, skin conductance, and
skin temperature).
Genetic Measures
The following genetic polymorphisms will be assayed: 1) C/T rs2023239 variant of the CB1R
gene, 2) the Ser/Gly rs6280 variant of DRD3 gene, and 3) variants of the CYP2A6 gene.
Secondary Measures
Secondary study measures include baseline smoking history, FTND, TCQ-SF, mood form, CO, and
urinary cotinine and 3-hydroxycotinine. The ratio of 3-hydroxycotinine/cotinine is a
phenotypic biomarker of the rate of nicotine metabolism, which has been shown to be
associated with CYP2A6 genotype, level of nicotine dependence, various smoking behaviors, and
treatment outcome.
- INCLUSION CRITERIA:
1. 18-64 year old males and females
2. smoking at least 10 cigarettes per day for at least 1 year
3. urinary cotinine level greater than or equal to 100 ng/ml (NicAlert reading
greater than or equal to 3)
4. medically and psychologically healthy as determined by screening criteria
EXCLUSION CRITERIA:
1. definite plan to reduce or quit tobacco use in the next 30 days
2. treatment for tobacco dependence in the past 3 months
3. use of nicotine replacement products, bupropion, or varenicline in the past 3 months
4. consumption of more than 15 alcoholic drinks per week during the past month
5. use of any illicit drug more than twice per week during the past month
6. current use of any medication that would interfere with the protocol in the opinion of
MAI
7. under the influence of a drug or alcohol at experimental sessions
8. pregnant, nursing, or become pregnant during the study
We found this trial at
1
site
Click here to add this to my saved trials
